Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADS

DBV Technologies is rated Buy following positive Phase 3 VITESSE results. My risk- and dilution-adju

DBV Technologies is rated a buy, with a 24% upside to a $17 FY 2027 price target as Viaskin nears BL

Châtillon, France, July 17, 2026 DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $15

DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript

DBV Technologies NASDAQ: DBVT said it is continuing preparations for a planned third-quarter 2026 Bi

Châtillon, France, July 16, 2026 DBV Te c hnologies Announces the Filing of its 2026 Half-Year Repor

DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.12) per share which missed the analy

Châtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financia

Châtillon, France, July 14, 2026 DBV Technologies to Report Second Quarter 2026 Financial Results an

AMF Regulated Information Châtillon, France, July 6, 2026 Half-Year Report on the DBV Technologies L

Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperf

DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Pat

Châtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Pe

Châtillon, France, June 23, 2026 DBV Technologies Announces Inclusion in the Euronext Tech Leaders I

DBV Technologies (DBVT) saw its shares surge in the last session with trading volume being higher th

Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Ann

In the Phase 3 VITESSE study, VIASKIN® Peanut Patch demonstrated statistically significant efficacy

Châtillon, France, June 8, 2026 DBV Technologies to Present New Positive Data from VITESSE Study and

Châtillon, France, June 5, 2026 DBV Technologies to Participate in the Goldman Sachs 47th Annual Glo

Châtillon, France, June 3, 2026 DBV Technologies Announces the Results of its 2026 Combined General

DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that the first

Châtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phas

Châtillon, France, May 13, 2026 Combined General Meeting of June 3, 2026 Procedures for Obtaining In

Guggenheim analyst Yatin Suneja reiterates DBV Technologies (NASDAQ:DBVT) with a Buy and maintain

Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperf

DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.11) per share which beat the analyst

DBV Tech (DBVT) maintains progress with BLA submission for VIASKIN peanut patch in children. Analyst

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analy

Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperf

Guggenheim analyst Yatin Suneja reiterates DBV Technologies (NASDAQ:DBVT) with a Buy and maintain

DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.23) per share which beat the analyst

Dow futures down 0.2%. Hesai Group -ADR shares drop 6.6% after reporting lower quarterly earnings an

Dow futures down 0.2%. Hesai Group -ADR shares drop 6.6% after reporting lower quarterly earnings an

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Pa

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped highe

HC Wainwright & Co. analyst Andrew S. Fein maintains DBV Technologies (NASDAQ:DBVT) with a Bu